HUTCHMED China Limited (HCM)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED to Announce 2026 Half-Year Financial Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and...

HUTCHMED Shares Rise After Positive Phase III Results Presented at EHA Congress (HCM)

HUTCHMED (NASDAQ:HCM) shares gained 2.4% in premarket trading on Friday after the company unveiled encouraging Phase III clinical trial results...

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02...

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”...

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited...